

HERMES DECLARATION EXHIBIT 15 – PART 7 OF 8

US005116360A

United States Patent [19]

[11] Patent Number: 5,116,360

Pinchuk et al.

[45] Date of Patent: May 26, 1992

[54] MESH COMPOSITE GRAFT

[75] Inventors: Leonard Pinchuk; John B. Martin, Jr., both of Miami; Bruce A. Weber, Pembroke Pines, all of Fla.

[73] Assignee: Corvita Corporation, Miami, Fla.

[21] Appl. No.: 634,425

[22] Filed: Dec. 27, 1990

[51] Int. Cl.³ A61F 2/06

[52] U.S. Cl. 623/1; 623/11; 623/12

[58] Field of Search 623/12, 1

[56] References Cited

U.S. PATENT DOCUMENTS

4,475,972 10/1984 Wong
4,969,896 11/1990 Shors 623/1

Primary Examiner—David Isabella

Assistant Examiner—Debra S. Brittingham

Attorney, Agent, or Firm—Lockwood, Alex, FitzGibbon & Cummings

[57] ABSTRACT

A mesh composite graft including an inner component, an outer component formed from strands of durable material, such as polyethylene terephthalate, and an intermediate component made from strands of biocompatible synthetic material having a melting point less than that of the durable material from which the outer component is formed and less than that of the biocompatible synthetic material from which the inner component of the graft is formed. By heating the graft to a temperature greater than the melting point of the material from which the intermediate component is formed but less than the melting point of the outer component material and less than the melting point of the material from which the inner component is formed, the components are bound by the melted intermediate component to provide a totally porous, compliant composite graft reinforced by the outer component.

19 Claims, 1 Drawing Sheet




FIG. 1





FIG. 2



MESH COMPOSITE GRAFT

BACKGROUND AND DESCRIPTION OF THE INVENTION

The present invention generally relates to implantable prostheses and the like and to methods for making same. More particularly, the invention relates to a graft, such as a vascular graft or AV-shunt, having a compliant porous inner component and a compliant porous load-bearing outer component, bound together by a porous intermediate component that is made of material having a melting point lower than that of the materials from which the inner and outer components are made. With the outer component bound by the intermediate component to the inner component, a porous, yet strengthened integral graft results.

Blood vessels are not straight, rigid tubes but elastic conduits made of a variety of materials and having a compliance that varies with functional considerations. For example, the venous system functions, in part, as the blood reservoir for the body. In order to be able to respond to a larger volume of blood sent into the system because of, for example, a change in arterial blood pressure, the vessels of the venous system must be sufficiently compliant so that they can distend. The arterial system functions as the body's pressure reservoir. In order to avoid the wide swings in the blood pressure and flow that are possible with every contraction and relaxation of the heart, yet be able to maintain sufficient blood pressure so that blood can be pushed into all regions of the body, including through the small-diameter arterioles and the microcirculatory bed, the arteries must have sufficient compliant strength to elastically expand and recoil without the marked distension of the venous system.

Conventional grafts, however, are generally made of materials and in shapes that provide a structure whose compliance is markedly different from that of the walls of the vessel to which they may be attached. Grafts having walls less compliant than that of the host vessel walls are problematic in that conditions, such as intimal hyperplasia and stenotic narrowing, may develop. Grafts with walls having greater compliance than that of the vessel to which the graft is attached are problematic in that a portion of the graft wall may balloon—that is, develop an aneurysm—after implantation.

Other known grafts, while they may be compliant, may not necessarily be made from biocompatible materials. The implantation of a graft made from such material may prompt a thrombogenic or immunological response with the resultant deleterious formation of microthrombi or microocclusions in and around the graft. Other grafts are made from generally non-porous materials, that, accordingly, do not facilitate the ingrowth of cells and tissue within the graft. The full incorporation of the graft into the surrounding host tissue is thereby frustrated. Still other conventional grafts are made from microporous textiles that require preclotting of the vessel wall with blood to prevent leakage of blood at implantation.

A demand therefore is present for an integral graft made from biocompatible materials and having a structure that has compliant strength similar to that of natural tissue but that is sufficiently porous so that the graft may become incorporated into the host tissue yet not leak blood. The present invention satisfies the demand.

The present invention includes a three component system, an inner component, an intermediate component, and an outer component. While the components may be made from materials having generally different melting points and different mechanical properties, at a minimum the inner component and outer component are made from a material or materials having a melting temperature higher than the material from which the intermediate component is made. More specifically, the inner component is porous and is made from a biocompatible synthetic material, preferably a polyurethane composition made with an aromatic polycarbonate intermediate, having a melting point that is, at a minimum, in excess of the melting point of the composition from which the intermediate component is formed (further discussed below).

There are many methods by which the inner component may be made, such as the many known methods used to produce porous compliant vascular prostheses. One such method is termed phase inversion or separation which involves dissolving a urethane in a solvent, such as dimethyl acetamide (DMA), forming a coat on a mandrel—such as by dipping the mandrel into the dissolved urethane—and then immersing the urethane coating in a solution such as water by which DMA may be dissolved, but not urethane, thereby causing the urethane to bead-up and form a porous matrix.

Another method by which the inner component may be formed is termed particle elution. The method utilizes water soluble particles such as salt (NaCl, MgCl₂, CaCO₂, etc.) polymers, such as polyvinylpyrrolidone, sugars etc. The particles are mixed or blended into a urethane composition, and after forming a graft from the mixture such as by dip coating or extruding the particle filled plastic, the particle is eluted out with a suitable solvent.

Additional methods include replamineform, that involves the dissolution of a matrix, such as that of a sea urchin, out of the urethane with hydrochloric acid, spray techniques where filaments or beads of urethane are sprayed onto a mandrel to produce a porous vascular graft, and electrostatic deposition of urethane fibers from solution.

However, the porous vascular graft preferred in this invention is prepared according to the method detailed in U.S. Pat. No. 4,475,972 to Wong. This patent is incorporated herein by reference. An antioxidant may be added to further prevent degradation of the fibers drawn of the material from which the inner component is made.

Regardless of the nature and method of manufacturing the porous inner component, the intermediate component is comprised of one or more layers of a biocompatible synthetic material, preferably a polyurethane material, having a melting point lower than the melting point of the material from which the inner component is formed and lower than the melting point of the material from which the outer component is made.

The outer component comprises a mesh network made of strands, fibers, beads or expanded versions of a durable material such as a composition of fluorocarbons, such as expanded polytetrafluoroethylene ("ePTFE")—commonly termed Teflon—or stable polyesters, such as preferably polyethylene terephthalate ("PET")—commonly termed Dacron. This material is preferably warp-knitted in a tricot or double tricot pattern and shaped in a tubular configuration. It can also be appreciated that the outer component can be woven, braided,

weft-knitted and the like with loose fibers, textured fibers and the like to provide increased compliance. With the three components in place, a composite graft according to the present invention is formed by heating the structure to a temperature at or above the melting point of the material from which the intermediate component is formed but below the melting temperature or temperatures of the material from which the outer component is formed and of the material from which the inner component is formed. In this temperature range, the intermediate component may melt without the melting of either the inner component and the outer component, thereby mechanically bonding the inner component to the outer component.

The multi-component system of the present invention provides a number of advantages over conventional grafts. The use of a durable material, such as PET or ePTFE, from which the outer component may be formed is advantageous because of the known strength that such material has in the body. Devices made from PET or ePTFE when implanted in the body are known to maintain their integrity for some three decades. Further advantageously, it has been found that a graft—made according to the present invention and in which PET is used to form the outer component—has a burst strength and a tensile strength that is some two times greater than that of a conventional graft. Such strength prevents the dilation of the vessel in response to, for example, an increase in blood flow and/or pressure, creep relaxation of the urethane, biodegradation of the urethane, plasticization of the urethane, etc. Decreases in the strength of PET that may occur after implantation due, for example, to the absorption of water after implantation, are minimal as Dacron has a low water absorption ability.

The use of a knitted pattern according to which the durable strands of the outer component may be configured is advantageous due to the increased compliance such a pattern provides. As stated above, a durable material such as PET is recognized as a strong yet not necessarily compliant material. However, by knitting the strands from which the outer component is formed into a network, a compliant reinforcing outer component is formed. The use of such a material from which to form the outer component in the three component system of the present invention advantageously provides a strengthened, yet compliant graft.

The winding of strands of synthetic material, such as polyurethane over a mandrel to form an inner component is further advantageous because of the resultant porosity of the component. While the intermediate component may be made porous, for example, by painting synthetic material over the inner component and utilizing the phase inversion method or the particle elution method to form a porous matrix, preferably the intermediate component is formed by winding strands of synthetic material, such as polyurethane over the inner component, to provide a highly porous network. Utilizing strands of PET configured in a knitted pattern to form the outer reinforcement component further provides a porous network. Advantageously, by combining these individually porous components together in a composite graft, a totally porous integral graft results. Porosity is an advantage in medical devices, such as vascular grafts, because an open structure allows vascular fluid to infiltrate and communicate to and from the surrounding tissue and the interior of the graft and allows the ingrowth of tissue to occur within the

graft. Accordingly, the device becomes better incorporated into the surrounding tissue, thereby further securing the device within the implantation site.

Uniting the three components into a single composite graft advantageously facilitates the use of the device. The graft may be implanted without the need for any assembly immediately prior to use. The graft may be also cut and/or sutured as a unit without the need for the separate cutting and/or suturing of each component. Methods for cutting the composite graft include scalpel, scissors, hot wires, shaped blades, and the like. The speed with which the graft may be implanted is a particularly distinct advantage since the device is implanted only when a patient is undergoing surgery.

The use of a polycarbonate intermediate rather than, for example, a polyether urethane to make the polyurethane material from which the inner component is preferably made is advantageous as the resultant inner component better resists degradation. The resistance to degradation is further aided by the addition of antioxidant to the material from which the inner component is formed.

It is, accordingly, a general object of the present invention to provide an improved graft.

Another object of the present invention is to provide an integral improved graft made from a composite of layers of synthetic materials.

It is also an object of the present invention to provide a graft that is totally porous thereby facilitating the incorporation of the graft into the site of implantation.

An additional object of the present invention is to provide an improved graft having an outer component which strengthens the device without significantly impairing the overall compliance of the graft.

These and other objects, features and advantages of this invention will be clearly understood and explained with reference to the accompanying drawings and through a consideration of the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

In the course of this description, reference will be made to the attached drawings, wherein:

FIG. 1 is a perspective view illustrating an embodiment of a composite vascular graft according to the present invention with an outer component of knitted durable material positioned over and bound by an intermediate component to an inner component; and

FIG. 2 is a cross sectional view of the composite vascular graft according to the present invention illustrated in FIG. 1.

DESCRIPTION OF THE PARTICULAR EMBODIMENTS

The present invention is a composite vascular graft—generally designated as 21 in FIGS. 1 and 2—comprised of an inner component 31, an intermediate component 41, and an outer component 61. The inner component will be described first.

Inner component 31 is fabricated from a biocompatible synthetic material, preferably polyurethane, having a melting temperature that is, at a minimum, greater than the melting temperature of the material from which the intermediate component is formed. Preferably, in those embodiments in which the inner component 31 is formed from polyurethane, it is made with an aromatic polycarbonate urethane. Polycarbonate urethanes are preferred over polyether urethanes due to

their superior biostability. The aromatic polycarbonate urethanes have melting points in the range of 150° C. to 230° C. This is in contrast to some aliphatic polycarbonate urethanes that have melting points between 90° C. and 130° C. It can also be appreciated that the inner member may be composed of non-urethane materials such as silicone rubber, polyolefins, fluoroelastomers, ePTFE, and the like. An antioxidant, such as Irganox 1010, may be added to the inner member to further prevent degradation of the strands from which the inner component is formed. The melting temperature of the material from which the inner component is preferably formed exceeds 150° C.

The methods by which the inner component 31 may be fabricated include those disclosed in U.S. Pat. No. 4,475,972 to Wong. According to a fabrication method taught in the Wong patent, termed "solution processing", the inner component material is dissolved in a solvent and forced out of one or more orifices to form one or more continuous fibers. The fibers are drawn directly onto a rotating mandrel. As the distributor or spinnerette reciprocates along the mandrel, non-woven strands are layered on top of each other to form porous, non-woven network of criss-crossing strands.

The intermediate layer 41 is formed of a biocompatible synthetic material, such as a polyolefin, a silicone thermoplastic material, etc., or preferably a polyurethane material having a melting temperature less than that of the materials from which the inner and outer components are formed. The intermediate layer can be drawn in the manner described in the Wong patent so that at least one fibrous layer is laid over the inner component 31 to form a porous intermediate layer. This intermediate layer can be spun from solution as described in the Wong patent or can be simply wound onto the inner layer from a spool of the biocompatible low melting point material. Alternatively, phase inversion or particle elution methods may be used to form a porous intermediate component. Examples of suitable low melting point biocompatible materials include the aliphatic polycarbonate or polyether urethanes with melting points of 90° C. to 130° C. The resultant porous, non-woven network of strands forming the intermediate component 41, as drawn over the inner component 31 form a unit 51 which facilitates the transmission of fluid.

Mesh 61, composed of strands of durable material, such as PET or ePTFE, knitted or woven in a generally elongated cylindrical shape and whose inner surface 63 is of a diameter equal to or slightly larger than the diameter of the outer surface 45 of the intermediate component 41, is fitted over the intermediate component 41. To provide compliance to the mesh network of strands from which the outer component is formed, the strands are configured preferably in a knitted pattern. Tricot or double tricot warp knit patterns are preferred. Double tricot patterns are further advantageous because they provide greater depth to the outer component 61 and thereby facilitate the acceptance of and retention of sutures and tissue ingrowth through the graft 21. Tricot or double tricot warp patterns are further advantageous in that they are generally more interlocking than other patterns and therefore resist "running". Other acceptable patterns according to which the strands of the outer component 61 may be formed include jersey or double jersey patterns, woven or braided and multiple layers of the above. Also, the

fibers comprising the outer structure may be textured or non-textured and be of a variety of deniers.

The outer component 61 as positioned over the inner component and intermediate component is heated to a temperature equal to or greater than the temperature at which the material from which the intermediate component 41 is formed melts but less than the temperature and/or temperatures at which the material or materials from which the outer component and from which the inner component 31 is formed melts. When the inner component 31 is formed from the preferred material described above, the components are heated to a temperature less than 150° C. but greater than the temperature at which the material from which the intermediate component 41 is formed melts, such as 110° C. By maintaining the three components at such a temperature for a period of time, such as ten minutes, the intermediate component melts thereby securing the outer component 61 and the inner component 31 to each other. To further ensure the secure full engagement of the outer component 61 by the melted intermediate component 41, the outer component 61 may be forcefully pressed into the intermediate component 41 during the heating step such as mechanically and/or with or under pressure. After heating, the united three components are cooled thereby providing an integral mesh composite graft 21.

A mesh composite graft 21 according to the present invention is totally porous and compliant, yet advantageously includes a load bearing component, the outer component 61, which adds strength to the graft and prevents the failure of the graft even in response to greater fluid volume pressures from within, creep relaxation of the inner member and possible biodegradation effects of the inner member.

The advantageous compliance of the composite graft may be adjusted by varying the number of strands from which the inner component and the intermediate component 41 are formed. The compliance of the composite graft 21 may be adjusted also by varying the materials from which the inner component 31 and the intermediate component 41 are formed while maintaining the relationship that the intermediate component 41 must melt at a lower temperature than the materials from which the outer component and the material from which inner component 31 is formed. The compliance of the mesh composite graft 21 may be adjusted further by adjusting the angle at which the strands of the inner component 31 and/or the strands of the outer component 61 are laid down—a higher angle provides a less compliant component and thereby a less compliant graft.

The compliance may be adjusted even further by altering the knitting parameters, such as courses and wales per inch, the stitch density, the fiber denier, the number of strands per filament, the composition of the fibers and filaments such as a mixture of PET and Spandex compositions and whether the outer member is knitted, woven or braided.

The advantageous overall porosity of the graft 21 may be adjusted also in a number of ways. In addition to varying the size and number of the strands from which the inner component 31 and intermediate component 41 are formed, the strands of each component may be drawn at different angles to provide decreased pore size and resultant decreased porosity. Similarly, the porosity of the outer component 61, and thereby the porosity of the composite graft 21 may be varied by varying the

size and/or number of the strands and stitch density used to make the outer component mesh.

It can also be appreciated that the outer component need not be a tube formed specifically for this purpose from materials as above but can also be made from a vascular graft preformed from a porous matrix material such as ePTFE. One such graft is manufactured by W. L. Gore and marketed as a Gore-Tex graft. The ePTFE graft may be sheathed over the previously described inner and intermediate components and heat fused into a similar composite graft described in this document. Similarly, the inner members may be a Gore-Tex graft, the intermediate component, a heat fusible thermoplastic, and the outer component, a Dacron knit.

Regardless of the configuration of the inner, intermediate and outer components of the graft, i.e. be it spun, salt eluted, phase inverted, wound with an outer PET mesh, or in which an ePTFE configuration is utilized, the resultant composite graft 21 as formed may be implanted in vascular locations and retained in place through conventional methods, such as suturing. The preferred use of PET, knitted in a preferred tricot or double tricot pattern, from which to make the outer component 61 of the graft 21 provides a graft having a greater thickness than grafts without such a load bearing component. The outer component 61 facilitates the greater retention of the sutures within the graft.

It will be understood that the embodiments of the present invention as described are illustrative of some of the applications of the principles of the present invention. Modifications may be made by those skilled in the art without departure from the spirit and scope of the invention.

We claim:

1. A composite graft for implantation within a host, comprising:
 - an inner component made from wound, criss-crossing layers of fibers of a first biocompatible synthetic material and shaped to form a porous generally elongated cylindrical shape having a lumen through which blood may flow, said inner component having an outer surface;
 - an intermediate compliant bonding component made from wound, criss-crossing layers of fiber of a second biocompatible synthetic material, said second material having a melting point lower than the melting point of said first material and lower than the melting point of polyethylene terephthalate, said intermediate component positioned generally over and substantially covering said outer surface of said inner component, said intermediate component being porous and having an outer surface;
 - said intermediate component as positioned over said outer surface of the inner component forming a fluid transmission unit;
 - an outer component made from a mesh formed from strands of matrices of durable material, said strands or matrices preformed in a generally elongated cylindrical shape having a lumen therethrough and a diameter which is approximately equal to the outside diameter of said intermediate component, said outer component is positioned over and substantially covering said outer surface of the intermediate component; wherein each said outer component and said inner component is bonded to said intermediate component when each of the compo-

nents is heated to a temperature less than the melting temperature of said first material and said durable material thereby securing said components to each other to form a totally porous mesh composition graft.

2. The mesh composite graft according to claim 1, wherein said biocompatible synthetic material from which said inner component is made is polyurethane.
3. The mesh composite graft according to claim 2, wherein said polyurethane is made with a polycarbonate intermediate.
4. The mesh composite graft according to claim 2, wherein said polyurethane is made with an aromatic polycarbonate urethane.
5. The mesh composite graft according to claim 1, wherein said biocompatible synthetic material from which said inner component is made is silicone rubber.
6. The mesh composite graft according to claim 1, wherein said biocompatible synthetic material from which said inner component is made is a polyolefin.
7. The mesh composite graft according to claim 1, wherein said biocompatible synthetic material from which said inner component is made is a fluoroelastomer.
8. The mesh composite graft according to claim 3, wherein said polyurethane includes an antioxidant to prevent degradation of said inner component.
9. The mesh composite graft according to claim 1, wherein said biocompatible synthetic material from which said intermediate component is made is polyurethane.
10. The mesh composite graft according to claim 9, wherein said polyurethane is an aliphatic polycarbonate.
11. The mesh composite graft according to claim 1, wherein said biocompatible synthetic material from which said intermediate component is made is a polyolefin.
12. The mesh composite graft according to claim 1, wherein said biocompatible synthetic material from which said intermediate component is made is a silicon thermoplastic material.
13. The mesh composite graft according to claim 1, wherein said outer component is further secured to said fluid transmission unit by pressing said outer component into said intermediate component during heating.
14. The mesh composite graft according to claim 1, wherein said mesh is formed by knitting said strands of polyethylene terephthalate.
15. The mesh composite graft according to claim 1, wherein said mesh is formed by knitting said strands of polyethylene terephthalate in a tricot pattern.
16. The mesh composite graft according to claim 1, wherein said mesh is formed by knitting said strands of polyethylene terephthalate in a double tricot pattern.
17. The mesh composite graft according to claim 2, wherein said mesh is formed from strands of expanded polytetrafluoroethylene.
18. The mesh composite graft according to claim 2, wherein said mesh is preformed from strands of polytetrafluoroethylene.
19. The mesh composite graft according to claim 2, wherein said mesh is a preformed porous matrix of expanded polytetrafluoroethylene.



BTH-782

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.
 Serial No.: 838,511 ✓ Art Unit: 1504
 Filed : February 19, 1992 Examiner: C. Raimund
 For : STERILIZED HETEROGENEOUS BRAIDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

December 2, 1992

(Date of Deposit)

Matthew S. Goodwin

Name of applicant, assignee, or Registered Representative

Matthew S. Goodwin
 (Signature)

DEC 10 1992

December 2, 1992

(Date of Signature)

GROUP 1500

Hon. Commissioner of Patents
 and Trademarks
 Washington, D.C. 20231

AMENDMENT

Dear Sir:

Please reconsider the above-identified application in view of the following remarks. These remarks are subdivided into a discussion of the claimed invention, and an analysis of the rejection, to facilitate an understanding of the significant differences between the cited art and the claimed invention.

Discussion of the Invention

A proper understanding of the invention is critical for appreciating the dissimilarities between the invention and the teachings of the cited references.

In a broad sense, the invention is a braided suture which contains dissimilar filaments of first and second fiber-forming materials. However, the proper characterization of the claimed suture goes far beyond this simple description.

The braided suture is made up of multifilament yarns. A multifilament yarn is a bundle of individual filaments which are integrated to form a single unit, that is, an individual multifilament yarn. The braided suture has a first and second set of these multifilament yarns in a braided construction. Each of the filaments of the first set of yarns is composed of a first fiber-forming material. Similarly, each of the filaments of the second set of yarns is composed of a second fiber-forming material.

The importance of the construction of the first and second set of yarns cannot be diminished. The braided construction is not accurately characterized by simply referring to a suture with filaments of dissimilar fiber-forming materials in a braided construction. Rather, filaments of a first fiber-forming material must be bundled to prepare a first set of multifilament yarns, and filaments of the second fiber-forming material must also be bundled to prepare the second set of multifilament yarns.

Once an understanding of the composition and construction of each set of first and second yarns is achieved, the importance of a further characterization of the braid construction can now be understood and appreciated. One yarn from the first set of yarns is in direct intertwining contact with a yarn from the second set of yarns. This limitation does not simply mean that the dissimilar filaments are fabricated into a braided construction, that is, dissimilar filaments are in "intertwining contact". Rather it is a multifilament yarn which is in direct intertwining contact with another multifilament yarn. Again, it is important to emphasize here that the multifilament yarns are integrated bundles of individual filaments, and it is this integrated bundle of filaments of a first fiber-forming material which is in direct intertwining

contact with another integrated bundle of individual filaments of a second fiber-forming material.

One way to accurately characterize the braided suture of this invention is to refer to it as a structured mechanical blend of dissimilar fiber-forming materials. The fiber-forming materials are first arranged into integrated bundles to form multifilament yarns and then these multifilament yarns are further arranged so that at least one yarn from the first set of yarns directly intertwines with a multifilament yarn from the second set of yarns. This can be contrasted with a random, braided construction where filaments of dissimilar fiber-forming materials are randomly braided with one another to form a braided suture.

The heterogeneous braids of this invention exhibit truly outstanding and surprising properties. The integrity of the braid and therefore its properties is due entirely to the mechanical interlocking or weaving of the individual multifilament yarns (see the specification at page 4, lines 30-33). In the preferred embodiment, each yarn from the first set of multifilament yarns is in direct intertwining contact with a yarn of the second set to achieve the maximum degree of mechanical blending of the dissimilar multifilament yarns (see the specification at page 6, lines 28-31, and claim 15). In this way, yarn compatibility can be further enhanced and the overall physical and biological properties of the heterogeneous braid can be further improved as well.

What is truly surprising with respect to the claimed heterogeneous braid construction is that certain bulk properties of the claimed braid are better than what one skilled in the art would expect. A skilled artisan would expect the properties of the braid to simply follow the "Rule of Mixtures", where the bulk property

measured would be estimated to be a weighted average of its component properties. Upon studying the Examples in the specification, it will be noted that the bending rigidity of the heterogeneous braids in Examples 1 and 2 do not follow the Rule of Mixtures, but surprisingly show an enhanced bending rigidity relative to the weighted average of their filament components. This behavior is not achieved when dissimilar individual filaments are randomly braided to form the braided suture.

In setting forth the claimed invention, the heterogeneous braid does not encompass braided sutures with randomly braided individual filaments, as described in detail above. Further, the claimed heterogeneous braid could not be construed to cover known braids which have a core of longitudinally extending yarns composed of filaments of a first fiber-forming material, and a sheath of braided yarns composed of a second set of filaments of a dissimilar fiber-forming material. This braid construction does not fall within the scope of the claimed braid because these sheath yarns are not in direct intertwining contact with any of the core yarns. In other words, none of the sheath yarns are braided about a core yarn, but simply shroud the core yarns to form the sheath construction.

Analysis of the Rejection

1. Claims 21 and 23 were rejected under 35 USC §102(b) as being clearly anticipated by Doddi et al. ("Doddi"). Doddi does not anticipate the claimed suture, and therefore this rejection should be withdrawn.

The Examiner has correctly pointed out that Doddi does indeed disclose a surgical suture comprising filaments of two different polymers in a braided configuration (column 9, lines 47-56).

However, as discussed in detail above, more is required to meet the limitations of the claimed suture than just a disclosure concerning filaments of two different polymers in a braided configuration. Doddi teaches nothing more than braiding individual filaments, and fails to provide any guidance as to how that braiding should be carried out. Therefore, one skilled in the art would be lead to believe that what Doddi had in mind was to simply braid individual filaments in a randomized fashion to fabricate a multifilament suture. It is important enough, however, to reemphasize again that the claimed braid requires the bundling of individual filaments into an integrated unit to form a multifilament yarn. It is this multifilament yarn which directly intertwines with another multifilament yarn to form Applicants' braid construction.

Since Doddi only teaches randomly braiding filaments of dissimilar fiber-forming materials, it does not anticipate the claimed braided suture. Doddi simply fails to enable one skilled in the art to construct a braided suture in the manner set forth by Applicants, and it is axiomatic that a reference which lacks enablement is deficient as a reference to anticipate a claimed invention. Accordingly, it is respectfully requested that the rejection of claims 21 and 23 under 35 USC §102(b) as being clearly anticipated by Doddi be withdrawn.

2. Claims 22 and 24 were rejected under 35 USC §103 as being unpatentable over Kaplan et al. ("Kaplan") taken with Doddi. The Examiner asserts it would have been obvious to substitute PET and PTFE fibers of Doddi for the filaments of Kaplan to arrive at Applicants' claimed suture. Applicants respectfully traverse this rejection for the reasons given below.

The Examiner correctly points out that Kaplan discloses a ligament prosthesis made from a core component and a braided sheath component as illustrated in Figures 3 and 4, and discussed at column 8, line 65, through column 9, line 34. However, Kaplan suffers from the same deficiencies as does Doddi, and therefore fails to teach or suggest the claimed braided suture.

Firstly, the Examiner has made specific reference to the Kaplan specification regarding the makeup of the core components and the sheath yarn component. The only component which has a braided construction is the sheath yarn component. It is clear from Figure 3 of Kaplan that none of the sheath yarn components are in direct intertwining contact with the core component. In other words, the sheath yarn component is a true "sheath" which shrouds the core but is not in any way integrally braided with the core. Therefore, since the core is not in a braided construction, its composition is irrelevant with respect to the claimed braided suture.

When the focus is shifted to the more relevant aspect of the Kaplan disclosure, specifically the sheath yarn component, the Examiner has correctly pointed out that the sheath yarn component may be "fabricated from individual filaments having more than two different chemical compositions, one or more of which optionally being non-absorbable". (Column 9, lines 25-28). However, Kaplan neither teaches nor suggests how his sheath yarn component is to be fabricated from these dissimilar individual filaments, nor is there any guidance to one skilled in the art as to how such dissimilar individual filaments are to be braided. Accordingly, just as was the case with the deficient Doddi reference, one skilled in the art could only be lead to randomly braid the dissimilar individual filaments into a braid construction.

The teaching of Kaplan once again lacks the essence of the claimed invention, which is: bundled filaments of a first fiber-forming material form a first set of a multifilament yarns, and at least one of these multifilament yarns is intertwined with a multifilament yarn composed of bundled filaments of a second fiber-forming material. To put it bluntly, Kaplan teaches randomized braiding, and the claimed suture sets forth a structured braid. This difference is not trivial, as pointed out with reference to the discussion of Applicant's specification, and particularly Examples 1 and 2.

It should also be pointed out here that even if Doddi and Kaplan were combined, their combined teachings would still fail to meet the limitations of the claimed braided suture. This is so because neither reference, taken singularly or in combination, discloses a structured braid set forth in the claims, but merely sets forth randomized braiding of individual filaments.

For all of the reasons given above, especially taken in light of the detailed discussion of the claimed braided suture and its surprising advantages, the rejection of claims 22 and 24 under 35 USC §103 as being unpatentable over Kaplan taken with Doddi is improper. Accordingly, it is respectfully requested that this rejection be withdrawn.


3. Applicants acknowledge with gratitude the withdrawal of the rejection of claims 21-24 under 35 USC §103 as being unpatentable over Burgess, expressed in the previous Office Action dated July 8, 1992. (Paper No. 3). It is presumed that Applicants' response to this rejection in their Amendment dated August 6, 1992, spelling out the distinctions between Burgess and the claimed

invention, clearly convinced the Examiner that the claimed surgical suture is patentable over this art.

4. The prior art made of record and not relied upon by the Examiner is duly noted, and does not affect the patentability of Applicants' claimed invention.

5. Since all formal requirements appear to have been met, and the claimed invention is patentable over the art of record or any other art of which Applicants are aware, Applicants respectfully solicit a Notice of Allowance at the Examiner's earliest convenience.

Respectfully submitted,


Matthew S. Goodwin
Attorney for Applicant
Reg. No. 32,839

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2794
December 2, 1992

Case Docket No.: ETH-782

In re application of Alastair W. Hunter et al.

Serial No. 838,311

Filed 21 December 19, 1992

For STABILIZED HETEROGENEOUS BRAIDS

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

[] No additional fee is enclosed because this application was filed prior to October 25, 1965 (effective date of Public Law 89-83).

[X] No additional fee is required.

[X] One stamped, self-addressed postcard for the PTO Mail Room date stamp.

[] Petition For Extension of Time and charge to Deposit Account of Appropriate Fee.

The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2)	(3)	(4)	(5)	(6)	(7)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL CLAIMS	* 24	minus	** 24	= 0	x \$22	= \$ 000.00
INDEP. CLAIMS	* 1	minus	*** 3	= 0	x \$74	= \$ 000.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT						\$ 000.00

* If the entry in Col. 2 is less than the entry in Col. 4, write "0" in Col. 5.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

[X] Charge \$ 000.00 to Deposit Account No. 10-750/ETH-782/MSG. Three copies of this sheet are enclosed.

[X] Please charge any additional fees in connection with the filing of this communication, or credit overpayment, to Deposit Account No. 10-750/ETH-782/MSG. Three copies of this sheet are enclosed.

[] A check in the amount of \$ _____ is attached.

Matthew S. Goodwin
 Attorney of Record
 Reg. No. 32,019

Matthew S. Goodwin
 Johnson & Johnson
 One Johnson & Johnson Plaza
 New Brunswick, New Jersey 08933-7003
 (908) 524-2791
 December 2, 1992

DePuy Mitek, Inc. v. Arthrex, Inc.
 C.A. No. 04-12457 PBS
DMI000243

In re Application of Alastair W. Hunter et al.

Serial No. 838,511

Filed February 19, 1992

For STERILIZED HETEROGENEOUS BRAIDS

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

[] No additional fee is enclosed because this application was filed prior to October 25, 1965 (effective date of Public Law 89-83).

[X] No additional fee is required.

[X] One stamped, self-addressed postcard for the PTO Mail Room date stamp.

[] Petition For Extension of Time and charge to Deposit Account of Appropriate Fee.

The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2)	(3)	(4)	(5)	(6)	(7)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL CLAIMS	* 24	minus	** 24	= 0	x \$22	= \$ 000.00
INDEP. CLAIMS	* 1	minus	*** 3	= 0	x \$74	= \$ 000.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT						\$ 000.00

* If the entry in Col.2 is less than the entry in Col.4, write "0" in Col.5
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

[X] Charge \$ 000.00 to Deposit Account No. 10-750/ETH-782/MSG. Three copies of this sheet are enclosed.

[X] Please charge any additional fees in connection with the filing of this communication, or credit overpayment, to Deposit Account No. 10-750/ETH-782/MSG. Three copies of this sheet are enclosed.

[] A check in the amount of \$ _____ is attached.

Attorney of Record
Reg. No. 32,019

Matthew S. Goodwin
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(908) 524-2791
December 2, 1992

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No.04-12457 PBS
DMI000244

In re application of Alastair W. Hunter et al.

Serial No. 838,511

Filed February 19, 1992

For STERILIZED HETEROGENEOUS BRAIDS

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DEC 10 1992

687 1500

Sir:

Transmitted herewith is an amendment in the above-identified application.

[] No additional fee is enclosed because this application was filed prior to October 25, 1965 (effective date of Public Law 89-83).

[X] No additional fee is required.

[X] One stamped, self-addressed postcard for the PTO Mail Room date stamp.

[] Petition For Extension of Time and charge to Deposit Account of Appropriate Fee.

The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2)	(3)	(4)	(5)	(6)	(7)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL CLAIMS	* 24	minus	** 24	= 0	x \$22	= \$ 000.00
INDEP. CLAIMS	* 1	minus	*** 3	= 0	x \$74	= \$ 000.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT						\$ 000.00

* If the entry in Col. 2 is less than the entry in Col. 4, write "0" in Col. 5.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

[X] Charge \$ 000.00 to Deposit Account No. 10-750/ETH-782/MSG. Three copies of this sheet are enclosed.

[X] Please charge any additional fees in connection with the filing of this communication, or credit overpayment, to Deposit Account No. 10-750/ETH-782/MSG. Three copies of this sheet are enclosed.

[] A check in the amount of \$ _____ is attached.

Attorney of Record
Reg. No. 32,019

Matthew S. Goodwin
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(908) 524-2791
December 2, 1992

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No. 04-12457 PBS
DMI000245


**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

 Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
07/838,511	02/19/92	HUNTER	ETH-782

 ROBERT L. MINIER
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933-7003

15N1

EXAMINER
RAYMOND, C

ART UNIT	PAPER NUMBER
1504	

DATE MAILED: 03/18/93

 This is a communication from the examiner in charge of your application.
COMMISSIONER OF PATENTS AND TRADEMARKS

- ☐ This application has been examined
 ☒ Responsive to communication filed on Dec. 2, 1992
☐ This action is made final.

A shortened statutory period for response to this action is set to expire 3 month(s), — days from the date of this letter.
 Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133

Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:

- | | |
|---|--|
| 1. <input type="checkbox"/> Notice of References Cited by Examiner, PTO-892. | 2. <input type="checkbox"/> Notice re Patent Drawing, PTO-948. |
| 3. <input type="checkbox"/> Notice of Art Cited by Applicant, PTO-1449. | 4. <input type="checkbox"/> Notice of Informal Patent Application, Form PTO-152. |
| 5. <input type="checkbox"/> Information on How to Effect Drawing Changes, PTO-1474. | 6. <input type="checkbox"/> _____ |

Part II SUMMARY OF ACTION

1. ☒ Claims 1 - 24 are pending in the application.

Of the above, claims 1 - 20 are withdrawn from consideration.

2. ☐ Claims _____ have been cancelled.

3. ☐ Claims _____ are allowed.

4. ☒ Claims 21 - 24 are rejected.

5. ☐ Claims _____ are objected to.

6. ☐ Claims _____ are subject to restriction or election requirement.

7. ☐ This application has been filed with informal drawings under 37 C.F.R. 1.85 which are acceptable for examination purposes.

8. ☐ Formal drawings are required in response to this Office action.

9. ☐ The corrected or substitute drawings have been received on _____. Under 37 C.F.R. 1.84 these drawings are ☐ acceptable ☐ not acceptable (see explanation or Notice re Patent Drawing, PTO-948).

10. ☐ The proposed additional or substitute sheet(s) of drawings, filed on _____ has (have) been ☐ approved by the examiner. ☐ disapproved by the examiner (see explanation).

11. ☐ The proposed drawing correction, filed on _____, has been ☐ approved. ☐ disapproved (see explanation).

12. ☐ Acknowledgment is made of the claim for priority under U.S.C. 119. The certified copy has ☐ been received ☐ not been received
☐ been filed in parent application, serial no. _____; filed on _____

13. ☐ Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.

14. ☐ Other

EXAMINER'S ACTION

PTOL-326 (Rev. 9-89)

 DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No. 04-12457 PBS
DMI000246

Serial No. 838,511

-2-

Art Unit 1504

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --
(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

Claim 21 is rejected under 35 U.S.C. § 102(e) as being anticipated by Kaplan et al.

Kaplan et al. discloses a connective tissue prosthesis comprising a braided sheath yarn component and a core yarn component. The braided sheath comprises braided filaments or braided filament bundles (column 9, lines 4-12). A sheath component containing filaments of different chemical compositions is specifically disclosed (column 9, lines 12-16). Claim 21 is therefore anticipated by Kaplan et al.

The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as

Serial No. 838,511

-3-

Art Unit 1504

prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

Claims 21-24 are rejected under 35 U.S.C. § 103 as being unpatentable over Doddi et al. taken with Kaplan et al.

Doddie et al. disclose a surgical suture comprising filaments of two different polymers in a braided configuration (column 9, lines 47-56). Suitable biocompatible, non absorbable filaments include PET and PTFE (column 9, lines 51-53).

Kaplan et al. discloses a ligament prosthesis comprising a core component and a braided sheath component. The core component is "made up of one or more biocompatible, essentially non-bioabsorbable..." filaments (column 9, lines 1-3). The sheath yarn component may be fabricated from one or more non-bioabsorbable fibers (column 9, lines 25-28). It would have been obvious to form the sheath component of the device of Kaplan et al. from PTFE and PET. PTFE is known to impart improved knot run down properties to sutures (see Block U.S. Pat. No. 3,527,650). PET is noted for its low cost and high strength. The core yarn component must be non-bioabsorbable (column 4, lines 45-46). Since PET is non-bioabsorbable, biocompatible and has the desirable properties noted above, its use as the core component would have been obvious. Claims 21 and 22 are therefore unpatentable over Doddie et al. taken

Serial No. 838,511

-4-

Art Unit 1504

with Kaplan et al.


Kaplan et al. fail to disclose the prosthesis of their invention connected to a needle. Prosthesis are, however, implanted in the body using a needle. Claims 23 and 24 are therefore unpatentable over Doddi et al. taken with Kaplan et al.

Applicant's arguments with respect to claims 21-24 have been considered but are deemed to be moot in view of the new grounds of rejection.

Any inquiry concerning this communication should be directed to Chris Raimund at telephone number (703) 308-2374.



C. Raimund:pdw
February 25, 1993



GEORGE F. LESMES
SUPERVISORY PATENT EXAMINER
GROUP 150



ETH-782

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.
 Serial No.: 838,511 Art Unit: 1504
 Filed : February 19, 1992 Examiner: C. Raimund
 For : STERILIZED HETEROGENEOUS BRAIDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

August 4, 1993
 (Date of Deposit)

Hal Brent Woodman
 Name of applicant, assignee, or Registered Representative

Hal Brent Woodman
 (Signature)

August 3, 1993
 (Date of Signature)

Hon. Commissioner of Patents
 and Trademarks
 Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Submitted herewith on Form PTO-1449, is a listing of documents known to the Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. §1.56. Copies of these documents are also being submitted.

These documents are being submitted after the first Office Action. Accordingly, the Patent and Trademark Office is authorized to charge Account No. 10-750/ETH-782/HBW the appropriate fee under 37 C.F.R. §1.17(p) for the citation of these documents. Three copies of this statement are included.

CS14107 09/08/93 07838511

10-0750 140 126

200.00CH

DePuy Mitek, Inc. v. Arthrex, Inc.
 C.A. No. 04-12457 PBS

DMI000250

Consideration of the cited documents and making the same of record in the prosecution of the above-noted application are respectfully requested.

Respectfully submitted,

Hal B. Woodrow
Hal B. Woodrow
Reg. No. 32,501

JOHNSON & JOHNSON
One Johnson and Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976

ETH-782

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.
Serial No.: 838,511 Art Unit: 1504
Filed : February 19, 1992 Examiner: C. Raimund
For : STERILIZED HETEROGENEOUS BRAIDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

August 4, 1993
(Date of Deposit)

Hal Brent Woodrow
Name of applicant, assignee, or Registered Representative

Hal Brent Woodrow
(Signature)

August 3, 1993
(Date of Signature)

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Submitted herewith on Form PTO-1449, is a listing of documents known to the Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. §1.56. Copies of these documents are also being submitted.

These documents are being submitted after the first Office Action. Accordingly, the Patent and Trademark Office is authorized to charge Account No. 10-750/ETH-782/HBW the appropriate fee under 37 C.F.R. §1.17(p) for the citation of these documents. Three copies of this statment are included.

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No.04-12457 PBS
DMI000252

Consideration of the cited documents and making the same of record in the prosecution of the above-noted application are respectfully requested.

Respectfully submitted,

Hal B. Woodrow
Hal B. Woodrow
Reg. No. 32,501

JOHNSON & JOHNSON
One Johnson and Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976

Sheet 1 of 1

Form 100-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Docket No.	Serial No.
	ETH-782	838,511
	Applicant	
	Alastair W. Hunter, et al.	
	Filing Date	Group Art Unit
	Feb. 19, 1992	1504

U.S. PATENT DOCUMENTS

Exam'r Init.	Document No.	Date	Name	Class	Sub Class	File Date
CWR	3,463,158	8/26/69	Edward Emil Schmitt, et al.	606	228	1/9/67
CWR	4,979,956	12/25/90	Thomas A. Silvestrini	623	13	7/10/89
CWR	3,636,956	1/25/72	Allan K. Schneider	128	335.5	5/13/70
CWR	4,141,087	2/27/79	Shalaby W. Shalaby, et al.	3	1	1/19/77
CWR	4,959,069	9/25/90	Karl W. Brennan, et al.	606	228	10/20/89

FOREIGN PATENT DOCUMENTS

Exam'r Init.	Document No.	Date	Country	Class	Sub Class	Translate Yes	No
CWR	GB 2 082 213	8/16/80	Great Britain			<input checked="" type="checkbox"/>	

OTHER REFERENCES (include author, title, date, pertinent pages, etc.)

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No. 04-12457 PBS
DMI000254

Examiner	Date Considered
<i>Chun R. Kim</i>	NOVEMBER 8, 1993

Examiners: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



DOCKET NO. ETH-782

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.

Serial No.: 838,511 Art Unit: 1504

Filed : February 19, 1992 Examiner: C. Raimund

For : STERILIZED HETEROGENEOUS BRAIDS

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231


ASSOCIATE POWER OF ATTORNEY

Sir:

In the matter of the above-identified application, I hereby appoint Hal Woodrow (Reg. No.32,501), whose postal address is One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933-7003, my associate attorney to prosecute said application, to make alterations and amendments therein, to file continuing applications claiming the benefit of said application, to receive the patent and to transact all business in the Patent Office connected with said application.

I request all communications with respect to said application be addressed to Audley A. Ciamporzero, Jr., One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933-7003. All telephone calls should be directed to Hal Woodrow at (908) 524-2976.

Signed at New Brunswick, in the County of Middlesex and State of New Jersey, this 3rd day of August, 1993.



Attorney for Applicant(s)
Jason Lipow Reg. No. 25509

One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976
DATED: August 3, 1993

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No.04-12457 PBS

DMI000255



CKET NO. ETH-782

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.

Serial No.: 838,511 Art Unit: 1504

Filed : February 19, 1992 Examiner: C. Raimund

For : STERILIZED HETEROGENEOUS BRAIDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

August 4, 1993
(Date of Deposit)

Hal B. Woodrow
Name of applicant, assignee, or Registered Representative

Hal B. Woodrow
(Signature)

August 3, 1993
(Date of Signature)

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

PETITION FOR EXTENSION OF TIME
AND AUTHORIZATION TO CHARGE
DEPOSIT ACCOUNT THEREFOR

Dear Sir:

Applicant(s) petition(s) the Commissioner of Patents and Trademarks to extend the time for response to the Office Action dated March 18, 1993 for two (2) month(s) from June 18, 1993 to August 18, 1993. An Amendment responding to the aforesaid Office Action is being filed concurrently herewith.

Please charge Deposit Account No. 10-750/ETH-782/HBW in the name of Johnson & Johnson for the cost of filing this Petition. Three copies of this Petition are enclosed.

P 30003 08/30/93 07838511

Respectfully submitted,
10-0750 030 116 360.00CH

Hal B. Woodrow
Hal B. Woodrow
Reg. No. 32051
Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976
DATE: August 4, 1993

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No.04-12457 PBS

DMI000256

JACKET NO. ETH-782



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.

Serial No.: 838,511

Art Unit: 1504

Filed : February 19, 1992 Examiner: C. Raimund

For : STERILIZED HETEROGENEOUS BRAIDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

August 4, 1993
(Date of Deposit)

Hal B. Woodrow
Name of applicant, assignee, or Registered Representative

Hal B. Woodrow
(Signature)

August 3, 1993
(Date of Signature)

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

SEP 1 1993

PETITION FOR EXTENSION OF TIME
AND AUTHORIZATION TO CHARGE
DEPOSIT ACCOUNT THEREFOR

Dear Sir:

Applicant(s) petition(s) the Commissioner of Patents and Trademarks to extend the time for response to the Office Action dated March 18, 1993 for two (2) month(s) from June 18, 1993 to August 18, 1993. An Amendment responding to the aforesaid Office Action is being filed concurrently herewith.

Please charge Deposit Account No. 10-750/ETH-782/HBW in the name of Johnson & Johnson for the cost of filing this Petition. Three copies of this Petition are enclosed.

Respectfully submitted,

Hal B. Woodrow
Hal B. Woodrow
Reg. No. 32051
Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976
DATE: August 4, 1993

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No. 04-12457 PBS

DMI000257



ETH-782

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.

Serial No.: 838,511

Art Unit: 1504

Filed : February 19, 1992

Examiner: C. Raimund

For : STERILIZED HETEROGENEOUS BRAIDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

August 4, 1993
(Date of Deposit)

Hai B. Woodrow
Name of Applicant, Assignee, or Registered Representative

Hai B. Woodrow
(Signature)

August 3, 1993
(Date of Signature)

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

AMENDMENT

Dear Sir:

This amendment is responsive to the Office Action of March 18, 1993.

IN THE CLAIMS

Please amend claim 2 as follows:

(Once Amended)

CM 1. A surgical suture [comprising] consisting essentially of a [the] heterogeneous braid [of claim 1] composed of a first and second set of continuous and discrete yarns in a sterilized, braided construction wherein at least one yarn from the first set is in direct intertwining contact with a yarn from the second set; and

PI a) each yarn from the first set is composed of a plurality of filaments of a first fiber-forming material selected from the group consisting of PTFE, FEP, PFA, PVDF, PETFE, PP and PE; and

PI b) each yarn from the second set is composed of a plurality of filaments of a second fiber-forming material selected from the group consisting of PET, nylon and aramid; and

PI c) optionally a core.

26

CLAIM 2

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No. 04-12457 PBS
DMI000258

REMARKS

C. Please note that the attorney prosecuting this application for the assignee, Johnson & Johnson, is now Hal Brent Woodrow (Reg. No. 32,501). This change has been authorized by the Associated Power Attorney submitted herewith. No change in the address for correspondence is necessary.

Claim 21 has been amend to place this claim in proper form for allowance. Claim 21 as amended claims a heterogeneous braid composed of a first and second set of yarns. The first set of yarns are made of a fiber-forming material selected from the group consisting of PTFE, FEP, PFA, PVDF, PETFE, PP, and PE materials. The second set of yarns are made of a fiber-forming material selected from the group consisting PET, nylon and aramid materials. Support for there amendments may be found in the specification on page 4, lines 12-22 and page 8, lines 3-23. Accordingly, applicants request entry of this amendment and reconsideration of claim 21.

The rejection of claim 21 under 35 U.S.C. §102(e) as being anticipated by Kaplan et al. has been reviewed. However, applicants respectfully submit that claim 21 as amended is not anticipated by Kaplan. Kaplan, as stated by the Examiner, describes a connective tissue prosthesis comprising a braided sheath yarn component and a core yarn component. The sheath yarn being a biocompatible yarn that is bioabsorbable or semi-bioabsorbable (column 9 lines 10-12). In one embodiment the sheath yarn could also contain a non-bioabsorbable yarn of one or more chemical composition (column 9 line 25-27). Claim 21 as amended does not claim a sheath yarn composed of a bioabsorbable yarn. Accordingly, Kaplan et al. does not anticipate claim 21 under 35 U.S.C. § 102(e). Therefore, applicants request reconsideration and withdrawal of the rejection of claim 21 as being anticipated by Kaplan et al.

Applicants have also reviewed the rejection of claims 21-24 under 35 U.S.C. § 103 as being unpatentable over Doddi et al. taken with Kaplan et al. However, applicants respectfully submit that claims 21-24 are patentable over these documents.

Doddi et al. describes (column 9, lines 46-56) multifilament sutures composed of p-dioxanone and/or 1,4 dioxepan-2-one and alkyl substituted derivatives that may be woven, braided or knitted, either alone or in combination with nonabsorbable fibers. Although Doddi is a significant contribution to the art, Doddi does not describe heterogeneous braids formed from a first set of yarn composed of a plurality of filaments formed from materials selected

from the group consisting of PTFE, FEP, PFA, PVDF, PETFE, PP and PE; and a second set of yarn composed from a plurality of filaments formed from materials selected from the group consisting of PET, nylon and aramid. Accordingly, Doddi alone would not render the present invention obvious.

Kaplan et al. as discussed previously describes a prosthesis comprising a core component and a braided sheath component. The sheath component which is designed to "erode over time" (column 9, line 52) to leave only the nonabsorbable core component. The sheath, however, may optionally have, in addition to the bioabsorbable sheath yarn, one or more non-bioabsorbable filaments. Applicants, therefore, respectfully submit that Kaplan does not suggest or disclose combining a first set of nonabsorbable yarns (i.e. PTFE) and a second set of nonabsorbable yarn (i.e. PET). In fact, Kaplan teaches away from this combination.

In column 2, Kaplan describe one of the objects of their invention as being "a prosthesis being formed of a composite yarn wherein an elastic core yarn is wrapped with a relatively inelastic, bioabsorbable or semi-absorbable sheath yarn so as to exhibit the stress-strain properties of natural tissue" (column 2, lines 36-41). In column 4, Kaplan describes fluorinated hydrocarbons, polypropylene and polyethylene as elastic core polymers as opposed to the inelastic sheath polymers desired in the sheath. Thus, Kaplan appears to suggest that the sheath yarns listed by the applicant in claim 21 should not be used as in sheaths. Applicants respectfully submit that in view of Kaplan teaching away from the present invention that the combination of Kaplan with Doddi does not render the present invention obvious. Accordingly, Applicants request reconsideration and withdrawal of the rejection of claims 21-24.

The citation of Block (U.S. Patent No. 3,527,650) has also been considered, but is respectfully submitted to be non-analogous art. Block describes the use of PTFE particles on the external surface of a PET suture as a lubricant. Block, however, does not suggest or disclose PTFE fiber as having a lubricating effect. Therefore, Block's use of PTFE particles does not suggest or disclose the use of PTFE fibers in braids.

Applicants also wish to alert the Examiner to the applicants' intent to change the inventorship because of the reduced scope of the claims. Dennis D. Jamiolkowski will no longer appear as an inventor if the present claims are allowed. Papers to effectuate this changed inventorship will be submitted when one or more of the present claims are indicated to be allowable.

Respectfully requested,

Hal B. Woodrow
Hal B. Woodrow
Reg. No. 32,501

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976
Date: August 31, 1995



GP 1504

ETH-782

[Handwritten signatures and initials]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alastair W. Hunter, et al.

Serial No.: 838,511

Art Unit: 1504

Filed : February 19, 1992

Examiner: C. Raimund

For : STERILIZED HETEROGENEOUS BRAIDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

RECEIVED GROUP 150

NOV 16 1993

November 9, 1993

(Date of Deposit)

Hal Brent Woodrow

Name of applicant, assignee, or Registered Representative:

Hal Brent Woodrow

(Signature)

November 9, 1993

(Date of Signature)

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

11-24-93
7560
Raimund

SUPPLEMENTAL AMENDMENT

Dear Sir:

This Supplemental Amendment is an amendment to the Amendment submitted on August 4, 1993.

REMARKS

Applicants have noticed that the Amendment of August 4, 1993 under the heading "In The Claims" states, "Please amend claim 2 as follows:", however, the claim designated as being amended is claim

*Noted - checked by Examiner -
M. Lerner (SPE)
12-30-93*

USSN 838,511

21. Applicants respectfully request this sentence be changed to read "Please amend claim 21 as follows:".

Hal Brent Woodrow
Hal Brent Woodrow
Reg. No. 32,501
Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976
November 9, 1993



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	INVENTOR	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
---------------	-------------	----------	-----------------------	---------------------

09/08/91

09/08/91

15N1/11.8

EXAMINER

ROBERT L. MINIER
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933 7003

ARTWORK

PAPER NUMBER

11/24/93

DATE MAILED:

NOTICE OF ALLOWABILITY

PART I

1. ☒ This communication is responsive to the Amendment filed August 9, 1993.
2. ☒ All the claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice Of Allowance And Issue Fee Due or other appropriate communication will be sent in due course.
3. ☒ The allowed claims are 21, 23, 24, 7, 8, 10-12, 14, 18-20.
4. ☐ The drawings filed on _____ are acceptable.
5. ☐ Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has ☐ been received. ☐ not been received. ☐ been filed in parent application Serial No. _____, filed on _____.
6. ☒ Note the attached Examiner's Amendment.
7. ☐ Note the attached Examiner Interview Summary Record, PTOL-413.
8. ☐ Note the attached Examiner's Statement of Reasons for Allowance.
9. ☐ Note the attached NOTICE OF REFERENCES CITED, PTO-892.
10. ☒ Note the attached INFORMATION DISCLOSURE CITATION, PTO-1449.

PART II

A SHORTENED STATUTORY PERIOD FOR RESPONSE to comply with the requirements noted below is set to EXPIRE THREE MONTHS FROM THE "DATE MAILED" indicated on this form. Failure to timely comply will result in the ABANDONMENT of this application. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

1. ☐ Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL APPLICATION, PTO-152, which discloses that the oath or declaration is deficient. A SUBSTITUTE OATH OR DECLARATION IS REQUIRED.
2. ☐ APPLICANT MUST MAKE THE DRAWING CHANGES INDICATED BELOW IN THE MANNER SET FORTH ON THE REVERSE SIDE OF THIS PAPER.
- a. ☐ Drawing informalities are indicated on the NOTICE RE PATENT DRAWINGS, PTO-948, attached hereto or to Paper No. _____ CORRECTION IS REQUIRED.
- b. ☐ The proposed drawing correction filed on _____ has been approved by the examiner. CORRECTION IS REQUIRED.
- c. ☐ Approved drawing corrections are described by the examiner in the attached EXAMINER'S AMENDMENT. CORRECTION IS REQUIRED.
- d. ☐ Formal drawings are now REQUIRED.

Any response to this letter should include in the upper right hand corner, the following information from the NOTICE OF ALLOWANCE AND ISSUE FEE DUE: ISSUE BATCH NUMBER, DATE OF THE NOTICE OF ALLOWANCE, AND SERIAL NUMBER.

Attachments:

- ☒ Examiner's Amendment
- ☐ Examiner Interview Summary Record, PTOL-413
- ☐ Reasons for Allowance
- ☐ Notice of References Cited, PTO-892
- ☒ Information Disclosure Citation, PTO-1449

- ☐ Notice of Informal Application, PTO-152
- ☐ Notice re Patent Drawings, PTO-948
- ☐ Listing of Bonded Draftsmen
- ☐ Other

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No. 04-12457 PBS
DMI000264

Serial Number: 07/838,511

-2-

Art Unit: 1504

Part III EXAMINER'S AMENDMENT

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Hal B. Woodrow on November 15, 1993.

Permission was given to amend the claims as follows:

Cancel claims 1, 6, 9, 13, 15, 16, 17 and 22.

In claims 7, 8, 10, 11, 12, 14, 18, 19 and 20, line 1, change "heterogeneous braid" to "surgical suture".

In claim 7, line 1, change "6" to "21".

In claim 10, line 1, change "9" to "8".


In claim 14, line 1, change "13" to "12".


In claim 18, line 1, change "17" to "14".

In claim 20, line 1, change "1" to "21".

In claim 24, line 1, change "22" to "14".

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chris Raimund whose telephone number is (703) 308-2374.


Chris Raimund/cwr
November 15, 1993


GEORGE F. LESMES
SUPERVISORY PATENT EXAMINER
GROUP 150


**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: Box ISSUE FEE
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

ROBERT L. WINIEN
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08923-7000

**NOTICE OF ALLOWANCE
AND ISSUE FEE DUE**

- ☐ Note attached communication from the Examiner
☐ This notice is issued in view of applicant's communication filed _____

SERIES CODE/SERIAL NO.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT	DATE MAILED
07/008,511	01/19/92	012	ARMSTRONG, J.	11/10/91
First Named Applicant	UNITED STATES OF AMERICA, ALASTAIR W.			

TITLE OF INVENTION: STERILIZED HETEROPHASEOUS BRANES

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN. TYPE	SMALL ENTITY	FEE DUE	DATE DUE
ETH-732	009-131.000	567	UTILITY	NO	\$1175.00	04/18/92

THE FEE DUE IS THE AMOUNT IN EFFECT AT THIS TIME. IF THE AMOUNT OF THE ISSUE FEE INCREASES PRIOR TO PAYMENT, APPLICANT WILL BE NOTIFIED OF THE BALANCE OF ISSUE FEE DUE.

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.

PROSECUTION ON THE MERITS IS CLOSED.

THE ISSUE FEE MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED.

HOW TO RESPOND TO THIS NOTICE:

- I. Review the SMALL ENTITY Status shown above.
If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

- A. If the status is changed, pay twice the amount of the FEE DUE shown above and notify the patent and Trademark Office of the change in status, or
B. If the Status is the same, pay the FEE DUE shown above.

If the SMALL ENTITY is shown as NO:


- A. Pay FEE DUE shown above, or
B. File verified statement of Small Entity Status before, or with, pay of 1/2 the FEE DUE shown above.

- II. Part B of this notice should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B should be completed and returned. If you are charging the ISSUE FEE to your deposit account, Part C of this notice should also be completed and returned.
- III. All communications regarding this application must give series code (or filing date) and serial number. Please direct all communications prior to issuance to Box ISSUE FEE unless advised to contrary.

IMPORTANT REMINDER: Patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B—ISSUE FEE TRANSMITTAL

MAILING INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE. Blocks 2 through 6 should be completed where appropriate. All further correspondence including the Issue Fee Receipt, the Patent, advances orders and notification of maintenance fees will be mailed to address entered in Block 1 unless you direct otherwise, by: (a) specifying a new correspondence address in Block below, or (b) providing the PTO with a separate "FEE ADDRESS" for maintenance fee notifications with the payment of Issue Fee or thereafter. See reverse for Certificate of Mailing.

1. CORRESPONDENCE ADDRESS	2. INVENTOR(S) ADDRESS CHANGE (Complete only if there is a change)
 <p>1500 1111</p> <p>JOHNSON PLAZA</p> <p>1000 1111</p>	INVENTOR'S NAME
	Street Address
	City, State and ZIP Code
	CO-INVENTOR'S NAME
	Street Address
	City, State and ZIP Code
	<input type="checkbox"/> Check if additional changes are on reverse side

SERIES CODE/SERIAL NO.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT	DATE MAILED
First Named Applicant				

TITLE OF INVENTION

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPL. TYPE	SMALL ENTITY	FEE DUE	DATE DUE
ETH-280	606-231.000	567	UTILITY	00	1111.00	02/22/94

3. Correspondence address change (Complete only if there is a change)	4. For printing on the patent front page, list the names of not more than 3 registered patent attorneys or agents OR alternatively, the name of a firm having as a member a registered attorney or agent. If no names are listed, no name will be printed.
<p>02/22/94 07838511/-</p> <p>02/22/94 07838511/-</p>	<p>Hal Brent Woodrow</p> <p>170.00CH</p> <p>30.00CH</p>

DO NOT USE THIS SPACE

5. ASSIGNMENT DATA TO BE PRINTED ON THE PATENT (print or type)		6a. The following fees are enclosed:	
(1) NAME OF ASSIGNEE:	Recorded- 2/19/92 Reel-6023	<input type="checkbox"/> Issue Fee	<input type="checkbox"/> Advanced Order - # of Copies (Minimum of 10)
(2) ADDRESS (CITY & STATE OR COUNTY)	Frame-941	6b. The following fees should be changed to:	
(3) STATE OF INCORPORATION, IF ASSIGNEE IS A CORPORATION	Ohio	DEPOSIT ACCOUNT NUMBER	10-0750
<p>A. <input type="checkbox"/> This application is NOT assigned.</p> <p><input checked="" type="checkbox"/> Assignment is being previously submitted to the Patent and Trademark Office.</p> <p><input type="checkbox"/> Assignment is being submitted under separate cover. Assignments should be directed to Box ASSIGNMENTS.</p> <p>PLEASE NOTE: Unless an assignee is identified in Block 5, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the PTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.</p>		(ENCLOSED PART C)	10
		<input checked="" type="checkbox"/> Issue Fee	<input checked="" type="checkbox"/> Advanced Order - # of Copies (Minimum of 10)
		<input type="checkbox"/> Any Delinquencies in Enclosed Fees	
		The COMMISSIONER OF PATENTS AND TRADEMARKS is requested to apply the Issue Fee to the application identified above.	
		(Signature of party in interest of record)	(Date)
		32,501 Hal Brent Woodrow	2/16/94
NOTE: This Issue Fee will not be collected from anyone other than the applicant, a registered attorney or agent, or the assignee or other party in interest as shown by the records of the Patent and Trademark Office.			

TRANSMIT THIS FORM WITH FEE CERTIFICATE OF MAILING ON REVERSE

PTOL-858 (REV.7-92)(OMB Clearance is pending)

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No.04-12457 PBS
DMI000267

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Box ISSUE FEE
Commissioner of Patents and Trademarks
Washington, D.C. 20231

OUT:
 94 FEB 18 PM 8:55
 PATENT & TRADEMARK OFC
 IRSB DIVISION

on February 16, 1994
(Date)

Hal Brent Woodrow
(Signature)

Hal Brent Woodrow
(Typed or Printed Name)


February 16, 1994
(Date)

Note: If this certificate of mailing is used, it can only be used to transmit the Issue Fee. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing.

This form is estimated to take 20 minutes to Complete. Time will vary depending upon the needs of the individual applicant. Any comments on the amount of time you require to complete this form should be sent to the Office of Management and Organization, Patent and Trademark Office, Washington, D.C. 20231 and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Washington, D.C. 20503.

PART B—ISSUE FEE TRANSMITTAL

MAILING INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE. Blocks 2 through 6 should be completed where appropriate. All further correspondence including the Issue Fee Receipt, the Patent, advances orders and notification of maintenance fees will be mailed to addressee entered in Block 1 unless you direct otherwise, by: (a) specifying a new correspondence address in Block below; or (b) providing the PTO with a separate "FEE ADDRESS" for maintenance fee notifications with the payment of Issue Fee or thereafter. See reverse for Certificate of Mailing.

1. CORRESPONDENCE ADDRESS		2. INVENTOR(S) ADDRESS CHANGE (Complete only if there is a change)	
 <p>ROBERT L. MITER ONE WASHINGTON PLAZA NEW BRUNSWICK, NJ 08902-7000</p>		<p>INVENTOR'S NAME</p> <p>Street Address</p> <p>City, State and ZIP Code</p> <p>CO-INVENTOR'S NAME</p> <p>Street Address</p> <p>City, State and ZIP Code</p> <p><input type="checkbox"/> Check if additional changes are on reverse side.</p>	

SERIES CODE/SERIAL NO.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT	DATE MAILED
First Named Applicant				

TITLE OF INVENTION		ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN. TYPE	SMALL ENTITY	FEE DUE	DATE DUE
ETH-100		606-201.000	507	UTILITY	NO	11170.00	02/18/94	

3. Correspondence address change (Complete only if there is a change)	4. For printing on the patent front page, list the names of not more than 3 registered patent attorneys or agents OR alternatively, the name of a firm having as a member a registered attorney or agent. If no name is listed, no name will be printed.
	1. Hal Brent Woodrow
	2. _____
	3. _____

DO NOT USE THIS SPACE

5. ASSIGNMENT DATA TO BE PRINTED ON THE PATENT (print or type)		6a. The following fees are enclosed:	
(1) NAME OF ASSIGNEE Ethicon, Inc. Recorded 2/19/92 Reel-6023		<input type="checkbox"/> Issue Fee <input type="checkbox"/> Advanced Order - # of Copies _____	
(2) ADDRESS (CITY & STATE OR COUNTRY) Somerville, N.J.		6b. The following fees should be changed to:	
(3) STATE OF INCORPORATION, IF ASSIGNEE IS A CORPORATION Ohio		90 DEPOSIT ACCOUNT NUMBER 10-0750	
A. <input type="checkbox"/> This application is NOT assigned.		(ENCLOSED PART C)	
<input checked="" type="checkbox"/> Assignment is being previously submitted to the Patent and Trademark Office.		<input checked="" type="checkbox"/> Issue Fee <input checked="" type="checkbox"/> Advanced Order - # of Copies 10	
<input type="checkbox"/> Assignment is being submitted under separate cover. Assignments should be directed to Box ASSIGNMENTS.		<input type="checkbox"/> Any Deficiencies in Enclosed Fees	
PLEASE NOTE: Unless an assignee is identified in Block 5, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the PTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.		The COMMISSIONER OF PATENTS AND TRADEMARKS is requested to apply the Issue Fee to the application identified above.	
		(Signature of party in interest of record)	
		32,501 Hal Brent Woodrow 2/16/94	
		NOTE: If the Issue Fee will not be accepted from anyone other than the applicant, a registered attorney or agent, or the assignee or other party in interest as shown by the records of the Patent and Trademark Office.	

TRANSMIT THIS FORM WITH FEE-CERTIFICATE OF MAILING ON REVERSE

PTOL-858 (REV. 7-82) (OMB Clearance is pending)

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No. 04-12457 PBS
DMI000269

PART B - ISSUE FEE

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Box ISSUE FEE

Commissioner of Patents and Trademarks
Washington, D.C. 20231

ON	February 16, 1994	(Date)
(Signature)	Hal Brent Woodward	
(Typed or Printed Name)	Hal Brent Woodward	
(Date)	February 16, 1994	

Note: If this certificate of mailing is used, it can only be used to transmit the Issue Fee. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing.

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No. 04-12457 PBS
DMI000270

This form is estimated to take 20 minutes to Complete. Time will vary depending upon the needs of the individual applicant. Any comments on the amount of time you require to complete this form should be sent to the

Office of Management and Organization, Patent and Trademark Office, Washington, D.C. 20231, and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Washington, D.C. 20503.

35,201
35,201
35,201

TRANSMIT THIS FORM WITH FEE CERTIFICATE OF MAILING ON REVERSE



ETH: 782
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Alastair W. Hunter, Dennis D. Jamiolkowski
 and Arthur Taylor, Jr.

Serial No. 07/838,511

Group No. 1504

Filed: February 19, 1992

Examiner: C. Raimund

For: STERILIZED HETEROGENOUS BRAIDS

CERTIFICATE OF MAILING (37 CFR 1.8(a))

RECEIVED

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Hal Brent Woodrow

Name of Person Mailing Paper

Date: November 22, 1993

Hal Brent Woodrow
 Signature of Person Mailing Paper

Commissioner of Patents and Trademarks
 Washington, D. C. 20231

12-6-93

7560

Raimund

AMENDMENT, PETITION AND FEE DELETING CORRECTLY NAMED
 ORIGINAL PERSON(S) WHO ARE NOT INVENTOR(S) OF INVENTION NOW
 BEING CLAIMED (37 CFR 1.48(b))

1. This amendment and petition under 37 CFR 1.48(b) is to delete the name(s) of the following person(s) originally named as inventor(s) of the invention now being claimed:

Dennis D. Jamiolkowski

2. Claims Now On File

The claims in this application are as follows:

[] originally filed claim(s) _____
 [] originally filed claims _____ as amended on _____

[] claim(s) _____ filed on _____

[X] claim(s) 21-24 filed on February 19, 1992 as amended on August 4, 1993 and amended by the Examiner's Amendment of November 15, 1993

P 30079 November 15, 1993

10-0750 1 0 100

170 0000

DePuy Mitek, Inc. v. Arthrex, Inc.
 C.A. No. 04-12457 PBS

DMI000271

USSN 07/838,511

[X] claims 25-33 added by the Examiner's Amendment of November 15, 1993

3. DILIGENCE

This amendment and petition is being filed

[X] diligently after discovery that any claim(s) for which the above-named inventor who is being deleted are now no longer the inventor of the subject matter being claimed.

4. STATUS OF INVENTORSHIP AFTER AMENDMENT

[] Attached is an explanation of the facts, including the ownership of all the claim(s) at the time the last claimed invention was made (Declaration of Inventorship and Common Ownership of Claims in Application).

5. FEE (37 CFR 1.17(h))

The fee required is paid as follow:

[X] charge Account No. 10-750/HBW/ETH-782 for any fee deficiency

[X] charge Account No. 10-750/HBW/ETH-782 the sum of \$130.00

Hal Brent Woodrow
Hal Brent Woodrow
Reg. No. 32,501

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(908) 524-2976
November 22, 1993

PTO UTILITY GRANT

Paper Number 14

*The
United
States
of
America*

The Commissioner of Patents
and Trademarks

*Has received an application for a patent
for a new and useful invention. The title
and description of the invention are en-
closed. The requirements of law have
been complied with, and it has been de-
termined that a patent on the invention
shall be granted under the law.*

Therefore, this

United States Patent

*Grants to the person or persons having
title to this patent the right to exclude
others from making, using or selling the
invention throughout the United States
of America for the term of seventeen
years from the date of this patent, sub-
ject to the payment of maintenance fees
as provided by law.*



Bence Lehman

Commissioner of Patents and Trademarks

Santha Z. Morton
Attest

PTO-1584

DePuy Mitek, Inc. v. Arthrex, Inc.
C.A. No.04-12457 PBS
DMI000273


**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

 Address COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	INTENTED APPLICANT	ATTORNEY/AGENT
4778 201511	02/19/92	HUNTER	1,141,111

 ROBERT L. MINIER
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933-7003

15N170527

EXAMINER

ART UNIT	PAPER NUMBER
----------	--------------

1504

DATE MAILED 05/27/94

- A. ☐ The petition filed _____ under 37 CFR 1.312(b) is granted.
The paper has been forwarded to the examiner for consideration on the merits.

- B. ☒ The amendment filed 2/16/94 under 37 CFR 1.312 has been considered, and has been:

1. ☐ entered
2. ☒ entered as directed to matters of form not affecting the scope of the invention (0.3311).
3. ☐ disapproved. A report appears below.
4. ☐ entered in part. A report appears below.

Report:

 SUPERVISOR
GROUP 150

PLEASE FURNISH YOUR ZIP CODE IN ALL CORRESPONDENCE

Fig. 2a, 1789





FIG. 2a, 1789



FIG. 2b, 1789



27
 □ - 100% NON-ABSORBABLE
 ▨ - 75% NON-ABSORBABLE - 25% PGA
 ▩ - 50% NON-ABSORBABLE - 50% PGA
 ▪ - 25% NON-ABSORBABLE - 75% PGA

FIG. 2c, 1789

INVENTORS
 EDWARD EMIL SCHMITT
 RUCCO ALBERT POLISTINA
 BY
 Samuel Brandt Helber
 ATTORNEY

FIG. 1








FIG. 2

INVENTORS
 EDWARD EMIL SCHMITT
 ROCCO ALBERT POLISTINA
 BY

Samuel Brandt
 ATTORNEY

U.S. PATENT AND TRADEMARK OFFICE
 RECEIVED
 SEP 11 2007



INVENTORS
 EDWARD EMIL SCHMITT
 ROCCO ALBERT POLISTINA
 BY
Samuel Brinkman
 ATTORNEY

FIG. 15



FIG. 15




FIG. 16




FIG. 17




FIG. 18

INVENTORS,
EDWARD EMIL SCHMITT
ROCCO ALBERT POLISTINA
BY

Samuel Brandt Trepp
ATTORNEY

U.S. 44, 126-334

§ 6. — 145

10. Results of the present study indicate that 5,000 cycles of low-voltage electrical stimulation (100 Hz, 100 μ s, 100 V) applied to the sciatic nerve of the rat with normal nerve conduction velocity is sufficient to produce a significant decrease in conduction velocity.

SUMMARY

13. In addition to the results mentioned above, the following observations were made. The majority of the fish taken in the vicinity are of the following species:

SUMMARY

15. "Persons in the system who are not employed by the State, but who are in the system are considered."

20. **Unsound or stifle.** A stifle joint is a joint in the leg, between the femur and tibia. It is a joint that is not completely fused, and it is a joint that is not completely fused.

"simple" is used to designate a group of shorter filaments which are usually twisted together to form a long, continuous thread.

Non-absorbable surgically acceptable filaments include
25 filaments of polyalkylenes, such as polyethylene, preferably linear polyethylene, with a density of about 0.9 or higher, or polypropylene, preferably isotactic polypropylene, or a polyamide, such as nylon, or a polyester, such as Dacron, or a polycrylamide, such as Celcon or
30 Crestan, or a halogenated polyalkylene, such as polytetrafluoroethylene, such as Teflon, or other halogenated polyalkylene, such as Kel-F or FEP, or cotton, or silk, or linen, or a metal such as stainless steel, titanium, silver, gold, or platinum. The above are the known non-absorbable material which is essentially inert in living
35 mammalian tissue, particularly human tissue, is usable as a non-absorbable filament. Those materials having a comparatively high tensile strength and flexibility are preferred.

40 An absorbable filament is one which is absorbed, that is, digested or dissolved, in living mammalian tissue.

A "thread" is a plurality of filaments, either continuous or staple, twisted together.

45 A "strand" is a plurality of filaments or threads twisted, plied, braided, or laid parallel to form a cord for further construction into a fabric, or used per se, or a monofilament of such size as to be woven or used independently.

pendently.

50 A "bi-component filament" is a filament composed of two separate materials. As used herein, the term is limited to a filament having one non-absorbable component and one absorbable component. The components may be adjacent. The most easily formed and preferred bi-component filament is a sheathed filament with an internal non-absorbable material coated, or sheathed, approximately

55 concentrically with an absorbable component.

A "bicomponent thread" includes a thread of bicomponent filaments or a blend of different separate monofilament components twisted together, or both.

60 A "two-component strand" is a strand of one or more bi-component filaments, or two different filament materials, or both, at least one component of which is absorbable.

A "bi-component fabric" is a woven, knitted, corded, adhesively united, or otherwise formed fabric of at least two dissimilar, or fabric and non-fabric, components of bi-component fibers or strands of two or more components, at least one component of which is non-elastic.

A "closed fabric" is a fabric characterized by a uniform continuous sheet of material, as for example by full-rail curtains, which form a closed system of well-defined fibers and threads, and which by their fabric structure and chemical composition are adapted to the use of an auto-

This application is a continuation-in-part of application Ser. No. 329,843, filed Oct. 31, 1963 now U.S. Patent 3,297,633, Jan. 10, 1967, "Surpical Sutures."

This invention relates to absorbable surgical elements of polyhydroxyacetic ester hereafter called polyglycolic acid (PGA).

Prior art

The use of submucosal tissue and ribbons therefrom is fully described in such patents as United States Patent 2,167,251, Rogers, "Surgical Tape of Sumozoia Tissue," July 25, 1939, United States Patent 2,141,910, Diodusich, "Ribbon Cut and Method of Using the Same," Jan. 17, 1939, and United States Patent 2,127,503, Bowen, "Tape for Surgical Purposes and Methods of Preparing and Using the Same," Aug. 23, 1938.

U.S.P. 2,936,181, J. S. Tapp, "Flexible Nylon Tube and Method for Preparing Same" shows a braided heat crimped formic acid treated nylon tube spliced into a blood vessel, with the crimp permitting a desired degree of flexibility.

U.S.P. 3,099,601, M. L. Edwards, "Heart Valve" shows a plastic cardiac valve, in which a fabric is employed in a ring around the valve, and sutured to the heart tissue, to permit the heart tissue to grow to such fabric, and hold the valve in position in the heart.

U.S.P. 3,054,406, F. C. Usher, "Surgical Mesh," Sept. 18, 1962, shows the use of a polyethylene woven mesh fabric implanted in the human abdominal wall for reinforcing and healing defects.

U.S.P. 3,108,557, W. J. Fichtig, "Compound Absorbable Prosthetic Implants, Fabrics and Yarns Thereof" shows flexible fabrics of mixed absorbable and non-absorbable textile fibers for implantation, and reinforcement of tissue.

U.S.P. 3,124,185, F. C. Usher, entitled "Reptilian Body Tissue," Mar. 10, 1964, shows the use of knitted linear polyethylene mesh attached to a variety of animal defects. The polyethylene is nonabsorbable and permanently reinforces the tissue at the site of the defect. Additional details appear in Usher, *Chemical Abstracts* 59:114,000 (U.S. or Mexico) Stein in the Report of Progress in the U.S. or Mexico in Surgery 24, 1964-1965, p. 10, 1965, 1966.

[illegible][illegible]


A "total artificial series" is a portion of bi-component fabric, or, if the component is a mesh, a very tight collection of strands for the fabric, or components for the strand or strands, has a changing composition over a short distance of 1 mm. to 15 mm. or more, so that a fabric or strand changes in composition from nonabsorbable material, or substantially nonabsorbable material, to predominantly or completely absorbable material, whereby living tissue can replace the absorbable component and a gradual transition accomplished between the nonabsorbable reinforcing prosthesis and the adjacent living tissue. With an arterial implant, for instance, a portion of the trouble has been the line of junction between the implant and the natural artery wall. With a gradual transition, no sharp line of demarcation exists, and hence, failures between the prosthesis and tissue are minimized. With implants of the type shown by Usher, supra, the edges of the reinforcing element could cause difficulties. With a gradual transition, a line of potential risk is eliminated.

For different purposes and in different types of tissue the rate of absorption may vary but in general an absorbable prosthesis should have a half absorption of its original strength as possible for at least three days, and sometimes as much as fifteen days or more, and preferably should be completely absorbed by muscular tissue within from forty-five to ninety days or more depending on the mass of the cross-section. The rate of absorption in other tissues may vary even more.

In common with many biological systems, the requirements are not absolute and the rate of absorption as well as the short-term strength requirement varies from patient to patient and at different locations within the body, as well as with the thickness of the section of PGA.

The PGA may be formed as tubes or sheets for surgical repair and may also be spun as thin filaments and woven or felted to form absorbable sponges or absorbable gauze, or used in conjunction with other structures as prosthetic devices, within the body of a human or animal where it is desirable that the structure have short-term strength, but be absorbable. The useful end-applications include tubes, including branched tubes or T's, for cannula, skin or mucosal repair, nerve sheathing, blood and saliva, sheets for lining and supporting damaged kidney, liver and other internal organs, protecting damaged surface areas such as abrasions, gums, ulcers, open wounds, or areas where the skin and underlying tissues are damaged or surgeonically removed.


The synthetic character and hence predictable formability and properties of the polymers are obtainable from a controlled process are fully demonstrated.

[illegible]

1. *Proteinase K* (Boehringer-Mannheim, Germany) was used at 10 mg/ml.

For the 24-month-old child, the instrument is a narrow vertical plate 248 × 60 mm, with a total of 200 × 100 points. The use of the Vibration scale has a standard and controlled source, with a controlled climate, in a world and controlled small percentage of variability, for the soft, dry, stiffest, and/or for character, they can be modified.

Among several methods by which PGA can be prepared, one preferred route involves the polymerization of glycolide.



the cyclic dimeric condensation product formed by dehydrating hydroxy- α -ene- β -ol. During polymerization of glycolide, the ring is broken and straight-chain polymerization occurs.

Small quantities of other materials may be present in the chain, as for example, olefinic acid, its especially active forms, homologs, and analogs. In general, plasticizers tend to interfere with crystallinity, orientation, etc., and weaken fibers, but are useful for sponges and films. Other substances may be present, such as dyes, antibiotics, antiseptics, anesthetics, and antioxidants. The surfaces of the fabric can be coated with a silicone, beeswax, and the like to modify the handling or absorption rate.

The polymerization of glycolide occurs by heating with or without a catalyst, or may be induced by radiation such as X-rays, gamma rays, electron beams, etc. Polymers may also be obtained by condensing glycolic acid or chloroacetic acid with or without a catalyst under a variety of conditions. Good moldable objects or films are most readily obtained when the mol. viscosity at 245°C. is about 400 to about 27,000 mpoises.

Polysilyloxyacetic esters have been described in United States Patent 2,658,163, Ito et al., "Preparation of High Molecular Weight Polysilyloxyacetic Ester," and United States Patent 2,676,945, Higgins, "Condensation Polymers of Hydroxyacetic Acid."

The processes described in the above 1-2 patents can be used for producing PGA from which prostheses may be made. Additives such as triphenyl phosphite or S-nitro-Nox, a diolide aromatic phenol, can be added as color stabilizers.

DRAWINGS

FIGURE 1 shows a cross section of a filament of filament of about 25 percent monomer. The monomer is oriented in the direction of the filament.

FIGURE 2. Percentage of total catch of *U. carolinensis* by month of capture

FIGURE 2

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840. 84

1. The first step is to identify the problem or question that needs to be answered. This involves understanding the context and the specific requirements of the task.

[illegible]

1900-1910 1883-1892 1873-1882

FIGURE 11. Interconversion of α and β

FIGURE 12. Power grid of the flow for

FIGURE 13 shows the sleeve of FIGURE 12.

FIGURE 14 shows the series of 16,000

FIGURE 15 is a portion of a boxcar

FIGURE 16 shows a portion of a leaf's

FIGURE 17 shows a broken bone, the

FIGURE 18 shows a broken tube, the

PGA for the construction of the protein

clearly indicated:

$$= 0.11' + 1.21' = 1.32'$$

EXAMPLE 2

1. *Journal of the American Medical Association*, 1997; 278: 1039-1044.

and will follow the 15, 16, and 17 of 1951.

1

[illegible]

Journal of Management Studies, 1987, 20(6), 611-624.

1. *Chlorophyll a* and *Chlorophyll b* were determined in the

1. *Chlorophyll a* and *Chlorophyll b* were determined by the method of Lichtenthaler and Whistler (1973).

19. The number of expected deaths is 1,000,000 times a base of about

of (1.20, 2.10) based on the weight of the submatrix

1. *Journal of the American Medical Association*, 1990; 263: 1033-1036.

33. *Journal of the American Medical Association*, 1977; 237: 1001-1002.

days after onset throughout the clinical episode is

⁵⁰ *Id.* at 115 (quoting *Id.* at 114 (quoting *Id.* at 113)).

1993, p. 148). In 1985, the National Academy of Sciences (NAS) published a report on the state of the art of the science of global climate change, which was the first major scientific assessment of the issue (NAS 1985, p. 1).

[illegible]

Address: 1, P.O. Box 100, 10000, 10000, 10000

Attached PCA, similarly, analyzed it used to form

...the growth, while the nerve is reconnection.

As is shown in the drawings, a bisymmetric filament

the nature of the dependent variable (Dogan 2011).

100% of PBA

of each material.

1. *Staphylococcus aureus* (ATCC 12228) and *Staphylococcus epidermidis* (ATCC 12228) were grown in TSB on the

1987 - *The Great American Novel*, by David Shields.

FIGURE 8

FIGURE 9

FIGURE 10

FIGURE 11

FIGURE 12

FIGURE 13

FIGURE 14

FIGURE 15

FIGURE 16

FIGURE 17

FIGURE 18

FIGURE 19

FIGURE 20

FIGURE 21

FIGURE 22

FIGURE 23

FIGURE 24

FIGURE 25

FIGURE 26

FIGURE 27

FIGURE 28

FIGURE 29

FIGURE 30

FIGURE 31

FIGURE 32

FIGURE 33

FIGURE 34

FIGURE 35

FIGURE 36

FIGURE 37

FIGURE 38

FIGURE 39

FIGURE 40

FIGURE 41

FIGURE 42

FIGURE 43

FIGURE 44

FIGURE 45

FIGURE 46

FIGURE 47

FIGURE 48

FIGURE 49

FIGURE 50

FIGURE 51

FIGURE 52

FIGURE 53

FIGURE 54

FIGURE 55

FIGURE 56

FIGURE 57

FIGURE 58

FIGURE 59

FIGURE 60

FIGURE 61

FIGURE 62

FIGURE 63

FIGURE 64

FIGURE 65

FIGURE 66

FIGURE 67

FIGURE 68

FIGURE 69

FIGURE 70

FIGURE 71

FIGURE 72

FIGURE 73

FIGURE 74

FIGURE 75

FIGURE 76

FIGURE 77

FIGURE 78

FIGURE 79

FIGURE 80

FIGURE 81

FIGURE 82

FIGURE 83

FIGURE 84

FIGURE 85

FIGURE 86

FIGURE 87

FIGURE 88

FIGURE 89

FIGURE 90

FIGURE 91

FIGURE 92

FIGURE 93

FIGURE 94

FIGURE 95

FIGURE 96

FIGURE 97

FIGURE 98

FIGURE 99

FIGURE 100

FIGURE 101

FIGURE 102

FIGURE 103

FIGURE 104

FIGURE 105

FIGURE 106

FIGURE 107

FIGURE 108

FIGURE 109

FIGURE 110

FIGURE 111

FIGURE 112

FIGURE 113

FIGURE 114

FIGURE 115

FIGURE 116

FIGURE 117

FIGURE 118

FIGURE 119

FIGURE 120

FIGURE 121

FIGURE 122

FIGURE 123

FIGURE 124

FIGURE 125

FIGURE 126

FIGURE 127

FIGURE 128

FIGURE 129

FIGURE 130

FIGURE 131

FIGURE 132

FIGURE 133

FIGURE 134

FIGURE 135

FIGURE 136

FIGURE 137

FIGURE 138

FIGURE 139

FIGURE 140

FIGURE 141

FIGURE 142

FIGURE 143

FIGURE 144

FIGURE 145

FIGURE 146

FIGURE 147

FIGURE 148

FIGURE 149

FIGURE 150

FIGURE 151

FIGURE 152

FIGURE 153

FIGURE 154

FIGURE 155

FIGURE 156

FIGURE 157

FIGURE 158

FIGURE 159

FIGURE 160

FIGURE 161

FIGURE 162

FIGURE 163

FIGURE 164

FIGURE 165

FIGURE 166

FIGURE 167

FIGURE 168

FIGURE 169

FIGURE 170

FIGURE 171

FIGURE 172

FIGURE 173

FIGURE 174

FIGURE 175

FIGURE 176

FIGURE 177

FIGURE 178

FIGURE 179

FIGURE 180

FIGURE 181

FIGURE 182

FIGURE 183

FIGURE 184

FIGURE 185

FIGURE 186

FIGURE 187

FIGURE 188

FIGURE 189

FIGURE 190

FIGURE 191

FIGURE 192

FIGURE 193

FIGURE 194

FIGURE 195

FIGURE 196

FIGURE 197

FIGURE 198

FIGURE 199

FIGURE 200

FIGURE 201

FIGURE 202

FIGURE 203

FIGURE 204

FIGURE 205

FIGURE 206

FIGURE 207

FIGURE 208

FIGURE 209

FIGURE 210

FIGURE 211

FIGURE 212

FIGURE 213

FIGURE 214

FIGURE 215

FIGURE 216

FIGURE 217

FIGURE 218

FIGURE 219

FIGURE 220

FIGURE 221

FIGURE 222

FIGURE 223

FIGURE 224

FIGURE 225

FIGURE 226

FIGURE 227

FIGURE 228

FIGURE 229

FIGURE 230

FIGURE 231

FIGURE 232

FIGURE 233

FIGURE 234

FIGURE 235

FIGURE 236

FIGURE 237

FIGURE 238

FIGURE 239

FIGURE 240

FIGURE 241

FIGURE 242

FIGURE 243

FIGURE 244

FIGURE 245

FIGURE 246

FIGURE 247

FIGURE 248

FIGURE 249

FIGURE 250

FIGURE 251

FIGURE 252

FIGURE 253

FIGURE 254

FIGURE 255

FIGURE 256

FIGURE 257

FIGURE 258

FIGURE 259

FIGURE 260

FIGURE 261

FIGURE 262

FIGURE 263

FIGURE 264

FIGURE 265

FIGURE 266

FIGURE 267

FIGURE 268

FIGURE 269

FIGURE 270

FIGURE 271

FIGURE 272

FIGURE 273

FIGURE 274

FIGURE 275

FIGURE 276

FIGURE 277

FIGURE 278

FIGURE 279

FIGURE 280

FIGURE 281

FIGURE 282

FIGURE 283

FIGURE 284

FIGURE

[illegible][illegible]

With both the experimental and control animals the course of healing was uneventful. The results were essentially identical to the first study. After several days the furrows were partially epithelialized and the effect of time on the implants was observed. As expected in the rats, only about three-tenths of the stainless steel pin was covered by soft tissue but since the internal space was largely occluded, where the metallic pin was present, there was no macrophage tissue.

Where the molal ratio of polyglycolic acid had been used, at six weeks the overall structure of the rod was essentially unchanged but there were fissures developing on the surface and the cut ends which had been sharply defined were somewhat rounded. The rod was somewhat softened on the surface. There was a pronounced increase in the amount of erosion of the PGA rod in water but this erosion was later associated with infestation or other adverse reaction. By the 24th week the rod of polyglycolic acid was essentially digested and the bone now showed normal tissue architecture.

EXAMPLE 5

At a stable bone plate affixed with absorbable pins

For any of the hind legs of rabbits were blasted as described in Example 4. The cut ends were reapproximated and immobilized by use of an internal support. A from a sheet of polyglycolic acid approximately 12 inch thick 14" wide and 1 inch long, shaped to conform precisely to the bone by softening the plastic with heat and pre-molding it about a metal rod of suitable diameter. The premolded plate was centrally located over the cut bone and while held in position, small holes were drilled through the plate and completely through the bone with a 1/16 inch drill, two holes on each side of the bone break. Small PGA nails about 1/16 inch long and slightly over 1/16 inch in diameter made by flattening rod of this diameter by pressing against a beveled surface were driven through the holes in the PGA plate and completely through the bone to hold the plate in place. The soft tissue was approximated, the lower leg splinted and the animal was returned to its cage. X-rays were taken weekly and after five were stained at 3, 6, 12, 13 and 24 weeks intervals. The leg which had been operated upon were carefully dissected to determine the fate of the small cells and implant and to determine the cause of failure. At 2 weeks the bone was just beginning to form. The PGA implant was centrally located above the bone break but the bone was broken and the PGA plate was broken and bent. At 3 weeks the bone was beginning to form and the PGA plate was broken and bent. At 6 weeks the bone was beginning to form and the PGA plate was broken and bent. At 12 weeks the bone was beginning to form and the PGA plate was broken and bent. At 13 weeks the bone was beginning to form and the PGA plate was broken and bent. At 24 weeks the bone was beginning to form and the PGA plate was broken and bent.

As a result, the *Journal of Management* has been able to publish a wide range of research, including empirical, theoretical, and qualitative studies, as well as research on a variety of management topics. This has helped to establish the journal as a leading source of information for researchers and practitioners alike.

Marshall's theory of the "good life" is the basis of his social philosophy and his concept of the "good society" is a political and teleological ideal. The "good society" is a society that is by definition a just society. It is a society that is based on a political system that is just and that is based on a political system that is just and that is based on a political system that is just. The "good society" is a society that is based on a political system that is just and that is based on a political system that is just. The "good society" is a society that is based on a political system that is just and that is based on a political system that is just.

In this example where the internal processes were to be used in rabbits, the boxes were only 50.5" in diameter.

The abdominal aorta was exposed by incision through the ventral wall and clamps separated by about 1 cm. incises were placed on the aorta and aorta just caudal to the renal artery. The approximately 1 cm of the abdominal aorta between the clamps was resected and a comparable length of aorta taken out as described.

placental length of pregnant nursing female as described above was taken in place. The clamps were removed, and the animal was allowed to lick and blood-tinged seeping hot material. The abdomen was then closed and the animal returned to its cage. Sacrifices were made at the end of 1, 3, 6, 12, and 18 weeks and the prethrombotic implant and the blood vessel removed.

The neighboring tissue was examined. After the first week there was little change in the phagocytosis. The pores of the filter were closed with fibrin and some new cell growth was noticeable at the cut ends of the blood vessel. By three weeks the fibrin clots had been partially replaced by new cells which represented the partial development of a pseudo-intimal lining extending from the ends of the original vessel. The polypoidal cells and filaments were still intact but were shown in places of surface erosion on microscopic examination. By 6 weeks the pseudo-intimal

macrophage infiltration. By 12 weeks the pseudo intima lining was complete. Blood vessels were beginning to develop in this tissue layer. Growth of cells was occurring through the pores of the prosthesis which were now substantially bridged by the observed diminution in size of the PGA filaments which were no longer continuous. Strial lines of the PGA filaments was evident but the complete development of the pseudo intima prevented the sheets from entering the blood stream where they could represent foci for clot formation. By the twelfth week the PGA was essentially replaced by tissue elements which formed a well vascularized multilaminar layer completely encasing the polyester filaments of the prosthesis. The picture at 18 weeks was similar to that at 12 weeks with more vascularization and better organization of the cells of the inner lining and outer surface of the prosthesis. There was a conspicuous absence of any inflammatory response or abnormal tissue reaction. The absorption of the poly lactic acid gave sufficient space in the fiber network to permit adequate cell growth and proper vascularization so that necrosis of tissue did not develop.

As far as inspection permits, similar results appear to be obtained in humans. Of course with humans, and larger animals proportionately sized prostheses must be used.

Weakness:

1. A surgical prosthesis comprising a non-absorbable filament shaped as a hook, a hinge connecting element, and a non-absorbable element, and a non-absorbable filament, in at least a part of the element, a structure consisting essentially of polymerized cells, whereby on implantation in living tissue, the non-absorbable and structure is

